Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Tryptamine Therapeutics ( (AU:ENP) ) has shared an announcement.
ASX-listed Entropy Neurodynamics Limited, associated with Tryptamine Therapeutics, has reported a change in director Jason Carroll’s holdings following an off‑market transfer of shares. Carroll acquired 2,500,000 ordinary fully paid shares for $75,000, increasing his direct holding from 54,300,000 to 56,800,000 shares and maintaining a substantial portfolio of various options with staggered vesting and expiry dates.
The transaction underscores continued director alignment with the company’s equity base, signalling confidence in the business as it progresses its development plans in the neurotherapeutics sector. The unchanged structure of his extensive option holdings suggests a focus on long-term incentives, which may be viewed positively by investors monitoring insider activity and governance practices.
The most recent analyst rating on (AU:ENP) stock is a Sell with a A$0.03 price target. To see the full list of analyst forecasts on Tryptamine Therapeutics stock, see the AU:ENP Stock Forecast page.
More about Tryptamine Therapeutics
Tryptamine Therapeutics, operating through Entropy Neurodynamics Limited, is an ASX-listed biotechnology company focused on developing therapeutics in the neuropsychiatric and neurological space. The company uses equity and option-based incentives to align directors’ and employees’ interests with long-term shareholder value as it advances its clinical and commercial objectives.
Average Trading Volume: 2,424,495
Technical Sentiment Signal: Sell
Current Market Cap: A$53.31M
Learn more about ENP stock on TipRanks’ Stock Analysis page.